[A biochemical theory of schizophrenia]
- PMID: 6151120
[A biochemical theory of schizophrenia]
Abstract
In addition to the dopamine hypothesis, a glutamate hypothesis has been recently discussed in the biochemical theories on the cause of schizophrenia. In schizophrenic patients less glutamic acid has been found in the cerebrospinal fluid. Glutamate is probably the most important excitatory transmitter of the mammalian forebrain. The liberation of glutamic acid in the striatum is inhibited by dopamine, more specifically by the D2 receptor, which is also though to be responsible for the antipsychotic effects of neuroleptic drugs. It seems possible that schizophrenia may be primarily caused by underfunction of glutamatergic corticostriatal and corticomesolimbic neurons rather than by overfunction of the dopaminergic system. The negative cognitive symptoms associated with schizophrenia would fit in with this hypothesis. The classical and the new atypical neuroleptic drugs show differential effects on glutamate and GABA in the brain tissue of the striatum and in the cerebrospinal fluid. Whereas sulpiride diminishes glutamate in the striatum and enhances glutamate in the cerebrospinal fluid, tiapride does not affect either of them. Correspondingly, tiapride does not show any antipsychotic effects. Haloperidol, on the other hand, enhances the GABA level in the striatum in a dose-related manner. These findings may perhaps prompt experimental research to find antipsychotic drugs with fewer side effects.
Similar articles
-
Novel pharmacological approaches to the treatment of schizophrenia.Dan Med Bull. 2000 Jun;47(3):151-67. Dan Med Bull. 2000. PMID: 10913983 Review.
-
[Biochemistry of schizophrenia and mechanism of action of neuroleptics].Sem Hop. 1982 Dec 2;58(44):2565-72. Sem Hop. 1982. PMID: 6130604 Review. French.
-
Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia.Neuroreport. 1995 Dec 15;6(18):2500-4. Neuroreport. 1995. PMID: 8741750
-
Mayo Seminars in Psychiatry: dopamine and schizophrenia--a review.J Clin Psychiatry. 1979 Sep;40(9):399-405. J Clin Psychiatry. 1979. PMID: 39063 Review.
-
Biochemistry and the schizophrenia. Old concepts and new hypothesis.J Nerv Ment Dis. 1981 Feb;169(2):90-9. J Nerv Ment Dis. 1981. PMID: 7009786 Review.
Cited by
-
[3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients.J Neural Transm. 1989;77(2-3):231-6. doi: 10.1007/BF01248936. J Neural Transm. 1989. PMID: 2547892
-
Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue.J Neural Transm Gen Sect. 1994;98(3):217-35. doi: 10.1007/BF01276538. J Neural Transm Gen Sect. 1994. PMID: 7748522
-
Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients.Psychopharmacology (Berl). 1990;101(3):324-31. doi: 10.1007/BF02244049. Psychopharmacology (Berl). 1990. PMID: 2362952 Clinical Trial.
-
Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans.Psychopharmacology (Berl). 1996 Apr;124(3):261-6. doi: 10.1007/BF02246666. Psychopharmacology (Berl). 1996. PMID: 8740048 Clinical Trial.
-
The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice.J Neural Transm. 1989;75(3):221-6. doi: 10.1007/BF01258633. J Neural Transm. 1989. PMID: 2538557
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical